|
Medicare has instructed carriers to accept HCPCS code Q3013 (this is a new code, not listed in HCPCS 2001) for Visudyne (verteporfin), the medication use in photodynamic therapy, when the treatment is coded 67221 (destruction of localized lesion of choroid [eg, choriidal neovasularization]; photodynamic therapy [includes intravenous infusion]). Effective July 1, carriers must accept Q3013 when billed with exudative senile macular degeneration (362.52), according to Medicare memorandum transmittal AB-01-37.
The program memorandum also orders that claims for 67221 must be denied when billed with 362.51 (nonexudative senile macular degeneration) or 362.50 (macular degeneration [senile], unspecified).
Medicare is not requiring a fluorescein angiogram (FA) with each claim. The program memorandum specifies, however, that carriers may require you to maintain the FA in the patient's file for audit purposes.
|
